All In Biotech

Drug Trial Radar · NCT07750925

Examining Lithium's Mechanism in Bipolar Disorder

Investigating the Acute Effect of Lithium on Visual and Non-visual Responses to Light in Healthy Individuals

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Sep 21, 2026

Primary completion

Apr 30, 2028

Study completion Apr 30, 2029

Sponsor

Lead sponsor
Northumbria UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Newcastle University; Northumberland, Tyne and Wear NHS Foundation Trust
First posted
Aug 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the current study is to examine the acute effect of lithium on the visual and non-visual responses to light in a sample of healthy participants. Our experiments will investigate the effects of lithium on light sensitivity at the level of the retina as well as central visual and non-visual pathways. Our primary hypothesis is that the administration of lithium to healthy volunteers will reduce the magnitude of a range of non-visual responses to light including melatonin suppression, alertness, performance, mood and electrophysiology in a manner that is dependent of the amount of lithium in the brain. To better understand the postulated effects of lithium on light sensitivity and to examine its relationship at the level of the retina, we will assess the visual and non-visual responses to light, as well as the distribution of lithium in the brain using a non-invasive imaging technique. In addition to that, we also aim to examine the impact of both lithium and light on a molecular level through whole blood transcriptome sequencing.

Conditions

  • Healthy
  • Bipolar

Interventions

  • Lithium carbonate (Priadel)Drug

    Oral lithium carbonate 600 mg daily for 7 days prior to the second laboratory assessment (and for both days while in the laboratory)

  • Controlled light exposureOther

    Participants undergo 90-minute dim light (\<1 lux) and light exposure (100-850 lux) conditions during laboratory assessments to evaluate visual and non-visual responses to light.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma melatonin change in response to light stimulationTime frame: Measured during the 90-minute light exposure session after 7 days of lithium treatment and after 7 days in the no-lithium condition (days 9-11 and 19-21).
  2. Brain lithium signal intensity measured by 7Li-MRITime frame: Measured once following 9 days of lithium carbonate administration (Day 21)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Northumbria University

    Newcastle upon Tyne, Tyne & Wear, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.